Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAF312 versus placebo crossover study in neurogenic detrusor overactivity due to spinal cord lesions
NL-OMON57761Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SAF312 in detrusor hyperreflexia (DH), overactive bladder (OAB), sponsored by Novartis. Planned start Dec 2011; status: withdrawn.
02
Drugs
SAF312
03
Conditions
detrusor hyperreflexia (DH)overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON57761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57761.